Posts

Showing posts with the label CDMO

SYNGENE "Putting Science to Work" Annual report synopsis FY20-21

Image
  SYNGENE  - An Introduction   Delivering science that makes a difference Syngene International Limited is an integrated research, development, and manufacturing organization providing services from early discovery and development to commercial manufacturing for small and large molecules. Researchers work in multiple therapeutic areas to meet the needs of bio-pharmaceuticals clients. It also serve the nutrition, animal health, consumer goods, and specialty chemicals sectors.  Their ability to deliver world-class solutions is driven by highly qualified team, including over 4,700 scientists, and supported by state-of-the-art infrastructure and market-leading technology. Syngene is headquartered in Bangalore, India. They have one research campus and two sites in Bangalore, one research campus in Hyderabad and one manufacturing campus in Mangalore. Syngene USA Inc., a US-based wholly-owned subsidiary of Syngene, supports US-based clients.  These facilities regularly clear regulatory inspec

Laurus Labs "We Promise, We Deliver" - Annual Report synopsis FY20-21

Image
  We are passionate. We exceed quality benchmarks. We transform patients’ lives.     Ever since we began our journey, we at Laurus Labs have consistently leveraged opportunities to build a sustainable and value-creating enterprise. The result is that we have now emerged as a leading integrated research and development (‘R&D’) driven pharmaceutical and biotechnology company in India. We have been moving up the value chain into formulations, and have invested in developing products and building facilities to meet the most stringent regulatory expectations. We expect the formulation business to gain further momentum led by higher capacity/ANDA pipeline build-up for the US market. Our strong presence in the different therapies, consistency in compliance, and forward integration into formulations business have cemented the position as an integrated niche pharma player. Moving forward, we are convinced that with the right people, coupled with a culture of innovation, we will continue to